A Multicenter, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50microg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50microg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOW-3
  • Most Recent Events

    • 01 Oct 2011 Results from this trial were included in a Marketing Authorisation Application submitted to the EMA.
    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
    • 27 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society, according to a Vectura media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top